Abstract:OBJECTIVE To observe the effect of DNA Sema4D gene silencing by RNA interfering on the proliferation, migration and invasion of human ovarian cancer SKOV3 cells, and to study the effect of pshRNASema4D on the growth of SKOV3 cells in transplanted tumor in nude mice. METHODS Recombinant plasmid pshRNASema4D-A, B and C were respectively transfected into SKOV3 cells by lipofetamine 2000, while cells transfected by plasmid vector pcDNA3.1 and cells untreated as control groups. RT-PCR was adopted to select the recombinant plasmid which showed the most optimal inhibition effect. RT-PCR and Western blot were used to detected the mRNA and protein expression of Sema4D in SKOV3 cells tranfected for 24, 48 and 72 hours. MTT assay was used to investigate the proliferation of the SKOV3 cells after trasnsfection. Transwell cell migration and invasion assays were used to investigate the migration and invasion abilities of the SKOV3 cells after trasnsfection. Human ovarian cancer model was established in nude mice, and the nude mice were treated with pshRNASema4D-B once every 3 days for 3 weeks. The bulk of the transplanted tumor was measured. RESULTS Three Sema4D-targeted short hairpin RNA (shRNA) A, B and C were successfully inserted into the plasmid vector pshRNA, and the coding sequences of the obtained shRNA were consistent with the designed fragment. The results indicated that both recombinant plasmid pshRNASema4D-A and B could effectively knock down the expression of Sema4D gene in human ovarian cancer cells, of which pshRNASema4D-B was the better choice, while no effect of pshRNASema4D-C was seen. RT-PCR results showed that the relative mRNA expression of Sema4D gene in SKOV3 cells transfected with pshRNA-Sema4D for 24, 48 and 72 hours were 0.401 ± 0.051, 0.120 ± 0.035 and 0.014 ± 0.015, respectively, which were significantly lower than that in SKOV3 cells transfected by empty vector and non-transfected cells at 72 hours after transfection. (0.521 ± 0.019, 0.536 ± 0.040,respectively, P < 0.05). The Westen blot analysis manifested that the relative expression of Sema4D protein of SKOV3 cells transfected by pshRNASema4D for 24, 48 and 72 hours were 0.196 ± 0.023, 0.074 ± 0.015 and 0.040 ± 0.014, respectively, which were significantly lower than that in SKOV3 cells transfected by empty vector and non-transfected cells at 72 hours after transfection. (0.275 ± 0.009, 0.282 ± 0.015, respectively, P < 0.05). Comparing with the empty vector-transfected and non-transfected cells, the proliferation, invasion and migration ability of SKOV3 cells transfected with pshRNA-Sema4D were obviously weakened. The pshRNASema4D-B significantly suppressed the growth of the SKOV3 cells-transplanted tumors in nude mice, and the IR (inhibitory rate) of pshRNASema 4D-B group was (61.0 ± 3.3)% (P < 0.05). CONCLUSIONS Sema4D can be successfully silenced by RNA interfering in human ovarian cancer SKOV3 cells. Downregulation of Sema4D can inhibit the proliferation, migration and invasion of ovarian cancer cells. The pshRNASema4D can significantly suppress the growth in transplanted tumor of human ovary cancer in nude mice. Sema4D may become a candidate gene of gene therapy of human ovarian cancer.

Role of Sema4D in Bone Metastasis of Breast Cancer

The Effect of Specific Inhibition of Semaphorin4C (sema4c) Gene Expression by Small Interfering RNA on the Malignant Behavior of Human Breast Cancer Cell Line MDA-MB-231

CircSEMA4B Inhibits the Progression of Breast Cancer by Encoding a Novel Protein SEMA4B-211aa and Regulating AKT Phosphorylation

Sema3A Inhibits Osteolytic Bone Metastasis of Non-small Cell Lung Cancer

The role of semaphorin 4D as a potential biomarker for antiangiogenic therapy in colorectal cancer

Dependency of Tamoxifen Sensitive and Resistant ER+ Breast Cancer Cells on Semaphorin 3C (SEMA3C) for Growth

SOX4 promotes the growth and metastasis of breast cancer

Expression of Semaphorin 3c in Breast Cancer and Its Impact on Adhesion and Invasion of Breast Cancer Cells

SEMA4b Inhibits MMP9 to Prevent Metastasis of Non-Small Cell Lung Cancer

Semaphorin 3A Inhibits Tumor Progression Via the Downregulation of Lin28B in Ovarian Cancer

MiR-214 Suppressed Ovarian Cancer and Negatively Regulated Semaphorin 4D

SEMA6D Differentially Regulates Proliferation, Migration, and Invasion of Breast Cell Lines

SEMA4B Inhibits Growth of Non-Small Cell Lung Cancer in Vitro and in Vivo.

Downregulation of Semaphorin-3F is Associated with Poor Prognostic Significance in Osteosarcoma Patients.

Reduced Expression of Semaphorin 4D and Plexin-B in Breast Cancer is Associated with Poorer Prognosis and the Potential Linkage with Oestrogen Receptor.

Sema3d Restrained Hepatocellular Carcinoma Progression Through Inactivating Pi3k/Akt Signaling Via Interaction with FLNA.

Semaphorin 4B promotes tumor progression and associates with immune infiltrates in lung adenocarcinoma

Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study

Prevention of alveolar bone loss in an osteoporotic animal model via interference of semaphorin 4d.

miR‐196b‐5p regulates osteoblast and osteoclast differentiation and bone homeostasis by targeting SEMA3A

[Effect of Semaphorin4d Gene Silencing on Malignant Behavior of Human Ovarian Cancer SKOV3 Cells].